期刊文献+

瓣膜置换术后应用左西孟坦的临床观察 被引量:3

Clinical application of Levosimendan after cardiac valve replacement
下载PDF
导出
摘要 目的观察左西孟坦在瓣膜置换术后应用的临床效果。方法二尖瓣置换术患者60例,随机分为常规治疗组和左西孟坦组,每组30例。术后常规治疗组给予强心、利尿等常规治疗,左西孟坦组在常规治疗组治疗基础上给予左西孟坦。比较两组患者治疗效果及恢复情况。结果术后左西孟坦组心肌损伤反应和呼吸机辅助时间与常规治疗组比较,差异有统计学意义(P<0.05),左西孟坦组心肌损伤反应和呼吸机辅助时间减少;左西孟坦组重症加强护理病房(ICU)停留时间与常规治疗组比较,差异有统计学意义(P<0.05),左西孟坦组ICU停留时间减少。结论左西孟坦用于心脏瓣膜置换术后患者可明显改善心功能,减轻心肌损伤反应,且不良反应少,值得临床推广。 Objective To observe the clinical application effect of Levosimendan in patients after valve replacement. Methods Sixty patients with mitral valve replacement were randomly divided into routine treatment group (group C) and Levosimendan group (group Z) with 30 cases in each group. The group C received conventional treatment such as cardic stimulants and diuresis, while the group Z received Levosimendan in addition to the conventional treatment. Treatment effect and recovery of the two groups were compared. Results After operation, the myocardial injury response was weakened and the ventilator-assistant and the ICU-stay time was shortened in the group Z compared with the group C, the differences were statistically significant (P〈 0.05). Conclusions Levosimendan can significantly improve cardiac function, reduce myocardial injury response and adverse reactions for patients after cardiac valve replacement, and it is worthy of promotion.
出处 《中国现代医学杂志》 CAS 北大核心 2017年第9期117-120,共4页 China Journal of Modern Medicine
关键词 左西孟坦 瓣膜置换术 脑钠肽 心功能 Levosimendan cardiac valve replacement brain natriuretic peptide cardiac function
  • 相关文献

参考文献7

二级参考文献91

  • 1孙晋瑞,王功霞,梁大连.新型抗心衰药—左西孟旦[J].齐鲁药事,2004,23(7):59-60. 被引量:5
  • 2刘彤,李立丰,李广平.左西孟旦在急性失代偿心力衰竭治疗中的应用进展[J].中华急诊医学杂志,2006,15(6):571-573. 被引量:6
  • 3曾娅莉,黄文芳,卢贤瑜.细胞凋亡时线粒体钙离子信号调节因素研究进展[J].国际检验医学杂志,2006,27(6):543-545. 被引量:21
  • 4杜昕.钙增敏剂应用现状.长城心脏快讯,2005,2(10):39-41.
  • 5Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J,2005,26:384-416.
  • 6Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dubutamine in severe lowoutput heart failure (the LIDO study):a randomised donble-blind trial.Lancet,2002,360:196-202.
  • 7Moiseyev VS,Poder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer,levosimendan,in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo-controlled,double-blind study (RUSSIAN).Eur Heart J,2002,23:1422-1432.
  • 8Cleland JG,Ghosh J,Freemantle N,et al.Clinical trials update and cumulative meta-analyses from the American College of Cardiology:WATCH,SCD-HeFT,DINAMIT,CASINO,INSPIRE,STRATUS-US,RlO-Lipids and cardiac resynchronisation therapy in heart failure.Eur J Heart Fail,2004,6:501-508.
  • 9McMurray JJ,Pfeffer MA.Heart failure.Lancet,2005,365:1877-1889.
  • 10Lloyd-Jones DM,Larsen MG,Leip EP,et al.Lifetime risk for developing congestive heart failure:the Framingham Heart Study.Circulation,2002,106:3068-3072.

共引文献146

同被引文献20

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部